AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01416220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
Study NCT03546686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
Study NCT03546686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy/Cryoablation
Description: US-guided core biopsy and cryoablation 7-10 days prior to surgery.
Study NCT03546686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard-of-care definitive surgery.
Study NCT03546686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
Study NCT03546686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
Study NCT04223479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Capsule
Description: The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
Study NCT04223479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
Study NCT04467905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
Study NCT04467905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Study NCT04080648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
Study NCT04080648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
Study NCT06597084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Description: 800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Study NCT06597084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
Study NCT06601205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 1 tablet daily until the day before surgery
Study NCT06601205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 1 tablet daily until the day before surgery
Study NCT06601205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily until the day before surgery
Study NCT06597903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL994
Description: In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid.
Study NCT06587165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N15-thymidine
Description: 50mg/kg (oral administration)
Study NCT03840915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
Study NCT03809559 — intervention group
Intervention type: DEVICE
Intervention: MRCP+
Description: Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
Study NCT01874431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Study NCT01874431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02367820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181 BID tablets
Description: NKTR-181 tablets 100-600 mg twice daily (BID)
Study NCT00710853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YiRen Qi gong
Description: One hour weekly class for 8 week duration
Study NCT00710853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: One hour weekly class for 8 week duration
Study NCT00710853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hatha yoga
Description: One hour weekly class for 8 week duration
Study NCT04374344 — intervention group
Intervention type: OTHER
Intervention: Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements
Description: Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
Study NCT01336803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: 5 mg/kg by intravenous (IV) administration
Study NCT01336803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
Study NCT02470910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study NCT03211754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: walnuts and almonds
Description: The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
Study NCT04806542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMR-group
Description: A mindfulness-based 8 week program.
Study NCT04806542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Individual counselling.
Study NCT03170037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard V-E ventilation technique
Description: For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
Study NCT03170037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reversal V-E ventilation technique
Description: While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
Study NCT02778854 — intervention group
Intervention type: GENETIC
Intervention: detection of driver mutation
Description: participants are received gene detection via the liquid biopsy
Study NCT03743285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system
Study NCT03743285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study NCT00822211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Study NCT00822211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Study NCT00822211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03193359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
Study NCT05314790 — intervention group
Intervention type: OTHER
Intervention: intervening Educational Program
Description: The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
Study NCT02220673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT 0.1%
Study NCT02220673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT 0.5%
Study NCT02220673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RMT-B
Study NCT02220673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for HFA-MDI
Study NCT02349373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An 8 week preconditioning period
Description: Receipt of a weekly running schedule through an online training diary.
Study NCT02349373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16 week training period
Description: Receipt of a weekly running schedule through an online training diary.
Study NCT04849494 — intervention group
Intervention type: OTHER
Intervention: ATS-DLD-78-C and ISAAC questionnaires
Description: Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history
Study NCT00614601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute(R)-Pancreatic Cancer Vaccine
Description: 100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
Study NCT04695743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Cognitive Stimulation Therapy
Description: Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
Study NCT03403218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case group
Description: assessment of quality on posture, transfers and displacement
Study NCT04579822 — intervention group
Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: quadrivalent influenza vaccination in the flu seasons
Study NCT02796625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painful Stimuli
Description: warm or painful heat administration
Study NCT00208780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Study NCT03034538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: 100mg
Study NCT03034538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: 200mg
Study NCT04275089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reia Vaginal Pessary
Description: Reia Vaginal Pessary
Study NCT00913237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
Study NCT00913237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
Study NCT00933855 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires and training workshop
Description: We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment
Study NCT03902925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection
Description: Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
Study NCT03902925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peribulbar injection
Description: Peribulbar injection of 4-6 ml of ropivacaine 10%
Study NCT02717403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete a self response electronic questionnaire at baseline, and at three and six months.
Study NCT02717403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Participant accesses Facebook page regarding rheumatoid arthritis.
Study NCT02717403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website
Description: Participant accesses Educational Website on the internet about rheumatoid arthritis.
Study NCT02717403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Interview
Description: Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
Study NCT00636077 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux HD-C4 Big
Description: Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
Study NCT00636077 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HD-C4 Small
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
Study NCT00636077 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optiflux 160NR
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
Study NCT00636077 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optiflux 200NR
Description: Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
Study NCT02350777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion
Description: For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
Study NCT02350777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Cell Selection System
Study NCT06592976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain Oral Probiotic (CDS22-formula)
Description: All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
Study NCT00470340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, gemcitabine, cisplatin, lipiodol
Description: Oxaliplatin, gemcitabine, cisplatin, lipiodol
Study NCT03018951 — intervention group
Intervention type: OTHER
Intervention: Tool Development meeting
Description: Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
Study NCT03018951 — intervention group
Intervention type: OTHER
Intervention: Pilot Test 1 assessment session
Description: Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.